Several hypotheses have been proposed to explain the lack of efficacy of anti-IL-17A therapy in treating Crohn’s disease; these hypotheses have included the complexity of Th17 biology, the role of IL-17A in yeast immunity, and the action of IL-17A on intestinal epithelium to promote barrier function15–17. The gene discussed is IL17A; the disease is Crohn disease.